Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

328 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.
Turkington RC, Knight LA, Blayney JK, Secrier M, Douglas R, Parkes EE, Sutton EK, Stevenson L, McManus D, Halliday S, McCavigan AM, Logan GE, Walker SM, Steele CJ, Perner J, Bornschein J, MacRae S, Miremadi A, McCarron E, McQuaid S, Arthur K, James JA, Eatock MM, O'Neill R, Noble F, Underwood TJ, Harkin DP, Salto-Tellez M, Fitzgerald RC, Kennedy RD; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group. Turkington RC, et al. Gut. 2019 Nov;68(11):1918-1927. doi: 10.1136/gutjnl-2018-317624. Epub 2019 Mar 9. Gut. 2019. PMID: 30852560 Free PMC article.
AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
Dunne PD, McArt DG, Blayney JK, Kalimutho M, Greer S, Wang T, Srivastava S, Ong CW, Arthur K, Loughrey M, Redmond K, Longley DB, Salto-Tellez M, Johnston PG, Van Schaeybroeck S. Dunne PD, et al. Clin Cancer Res. 2014 Jan 1;20(1):164-75. doi: 10.1158/1078-0432.CCR-13-1354. Epub 2013 Oct 29. Clin Cancer Res. 2014. PMID: 24170546 Free PMC article.
Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer.
Mulligan JM, Hill LA, Deharo S, Irwin G, Boyle D, Keating KE, Raji OY, McDyer FA, O'Brien E, Bylesjo M, Quinn JE, Lindor NM, Mullan PB, James CR, Walker SM, Kerr P, James J, Davison TS, Proutski V, Salto-Tellez M, Johnston PG, Couch FJ, Paul Harkin D, Kennedy RD. Mulligan JM, et al. J Natl Cancer Inst. 2014 Jan;106(1):djt335. doi: 10.1093/jnci/djt335. J Natl Cancer Inst. 2014. PMID: 24402422 Free PMC article.
TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities.
D'Costa ZC, Higgins C, Ong CW, Irwin GW, Boyle D, McArt DG, McCloskey K, Buckley NE, Crawford NT, Thiagarajan L, Murray JT, Kennedy RD, Mulligan KA, Harkin DP, Waugh DJ, Scott CJ, Salto-Tellez M, Williams R, Mullan PB. D'Costa ZC, et al. Oncotarget. 2014 Mar 30;5(6):1609-20. doi: 10.18632/oncotarget.1707. Oncotarget. 2014. PMID: 24742492 Free PMC article.
328 results